Idorsia, Allschwil, Switzerland
MULTIVALENT VACCINE TARGETING KLEBSIELLA PNEUMONIAE
Prophylactic semi-synthetic O antigen conjugate vaccine
Klebsiella pneumoniae is a superbug that has spread around the world. Incidence of virtually all strains, including those with multi-resistant profiles, is increasing rapidly. Prevention of infection is a critical component to its abatement. Idorsia is developing a multivalent conjugate vaccine with synthetically produced O-antigens to target more than 80% of carbapenem resistant strains. Efficacy of valencies has already been demonstrated in various mouse and rabbit infection models. The work performed with CARB-X support, initiated with Vaxxilon, includes completion of lead optimization and preclinical development, GMP manufacturing, and a Phase I clinical trial.
Current Development Stage: Hit to Lead
CARB-X Investment: Initial investment of up to $1.4m with potential option payments up to $3.1m
Initial CARB-X Investment Date: April 1, 2019